1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Apical Sodium-Dependent Bile Acid Transporter

Apical Sodium-Dependent Bile Acid Transporter (顶端钠依赖性胆酸转运体)

ASBT; Ileal Bile Acid Transporter; IBAT; SLC10A2

Apical sodium-dependent bile acid transporter (ASBT, also known as IBAT-ileal bile acid transporter, SLC10A2) an ileal Na+-dependent transporter, actively reabsorbs bile acids (BAs) from the gut lumen. Bile acids are synthesized in the liver, stored in the gallbladder, and secreted into the duodenum at meals. ASBT is found on the brush border/apical membrane of ileal enterocytes, as well as the apical surface of renal tubules and cholangiocytes. Conjugated bile acids are actively transported by IBAT from the lumen/ apical side into the interior of the enterocyte and exported via the basolateral membrane organic solute transporter α/β heterodimer (OSTα/β; encoded by SLC51A/B) into the portal circulation, which allows for return of bile acids back to the liver. This process is a critical step in the enterohepatic circulation (EHC) of BAs and plays important roles in the homeostasis of BAs in the body. Therefore, ASBT is considered a favorite target for intervention to regulate the levels of BAs, cholesterol, lipid and glucose etc. In addition, ASBT is also a popular delivery target for developing prodrugs, due to its intestinal localization, high expression and high uptake capacity.

Apical Sodium-Dependent Bile Acid Transporter 相关产品 (10):

目录号 产品名 作用方式 纯度
  • HY-109120
    Odevixibat 99.85%
    Odevixibat (A4250) 是一种有效的选择性回肠胆汁酸转运蛋白 (IBAT) 抑制剂。Odevixibat (A4250) 可减轻小鼠模型中的胆汁淤积性肝和胆管损伤。Odevixibat (A4250)可用于原发性胆汁性肝硬化的研究。
  • HY-16643
    Linerixibat 99.98%
    Linerixibat (GSK2330672) 是一种高效,不可吸收且具有口服活性的顶端钠依赖性胆汁酸转运蛋白 (ASBT) 抑制剂,对人 ASBTIC50 为 42 nM。Linerixibat 可用作降脂剂,具有研究 2 型糖尿病和原发性胆源性胆管炎的潜力。
  • HY-15790
    Elobixibat 99.88%
    Elobixibat 是有效的 ileal bile acid transporter (IBAT) 抑制剂, IC50 值分别为 0.53±0.17 nM (人类 IBAT), 0.13±0.03 nM (小鼠 IBAT), 5.8±1.6 nM (犬类 IBAT)。
  • HY-16747
    Maralixibat chloride Inhibitor 99.08%
    Maralixibat (SHP625) chloride 是一种口服活性回肠胆汁酸转运体 (IBAT) 抑制剂。(IBAT) 可用于研究罕见的胆汁淤积性肝病,包括 Alagille 综合征 (ALGS)、进行性家族性肝内胆汁淤积症 (PFIC) 和胆道闭锁。
  • HY-129982
    SC-435 98.73%
    SC-435 是顶端钠依赖性胆汁酸 (BA) 转运蛋白抑制剂。SC-435 可以改变肝胆固醇代谢以及降低血浆胆固醇浓度。
  • HY-101190
    Volixibat (SHP626;LUM002) 是一种高选择性、低吸收、竞争性的顶端钠依赖性胆汁酸转运体 (ASBT) 抑制剂。Volixibat 有潜力用于非酒精性脂肪性肝炎 (NASH) 的研究。
  • HY-15790A
    Elobixibat hydrate
    Elobixibat hydrate 是一种有效的胆汁酸转运体 ( IBAT) 抑制剂,其 IC50 值分别为 0.53±0.17 nM (人类 IBAT),0.13±0.03 nM (小鼠 IBAT),5.8±1.6 nM (犬类 IBAT)。Elobixibat hydrate 可用于老年慢性功能性便秘 (CIC) 的研究。
  • HY-148795
    Ritivixibat Inhibitor
    Ritivixibat 是回肠胆汁酸转运蛋白 (IBAT) 的抑制剂,也是胆汁酸调节剂。Ritivixibat 可用于心血管疾病、脂肪酸代谢和葡萄糖利用障碍、胃肠道疾病和肝脏疾病的研究。
  • HY-19264
    264W94 是有效的回肠胆汁酸转运蛋白 (IBAT) 抑制剂,是新型降胆固醇药。264W94 具有 CYP7A1 诱导作用和抗血脂作用。
  • HY-19298
    S-8921 是一种回肠 Na+/胆汁酸协同转运蛋白 (IBAT) 的抑制剂。